Abstract. Intrusion detection is a surveillance problem of practical import that is well suited to wireless sensor networks. In this paper, we study the application of sensor networks to the intrusion detection problem and the related problems of classifying and tracking targets. Our approach is based on a dense, distributed, wireless network of multi-modal resource-poor sensors combined into loosely coherent sensor arrays that perform in situ detection, estimation, compression, and exfiltration. We ground our study in the context of a security scenario called "A Line in the Sand" and accordingly define the target, system, environment, and fault models. Based on the performance requirements of the scenario and the sensing, communication, energy, and computation ability of the sensor network, we explore the design space of sensors, signal processing algorithms, communications, networking, and middleware services. We introduce the influence field, which can be estimated from a network of binary sensors, as the basis for a novel classifier. A contribution of our work is that we do not assume a reliable network; on the contrary, we quantitatively analyze the effects of network unreliability on application performance. Our work includes multiple experimental deployments of over 90 sensors nodes at MacDill Air Force Base in Tampa, Florida, as well as other field experiments of comparable scale. Based on these experiences, we identify a set of key lessons and articulate a few of the challenges facing extreme scaling to tens or hundreds of thousands of sensor nodes.

No abstract

No abstract

No abstract

Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a chronic and progressive disorder characterised by angioproliferative vasculopathy in the pulmonary arterioles, leading to endothelial and smooth muscle proliferation and dysfunction, inflammation and thrombosis. These changes increase pulmonary vascular resistance and subsequent pulmonary arterial pressure, causing right ventricular failure which leads to eventual death if untreated. The management of PAH has advanced rapidly in recent years due to improved understanding of the condition’s pathophysiology, specifically the nitric oxide, prostacyclin-thromboxane and endothelin-1 pathways. Five classes of drugs targeting these pathways are now available: phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, prostacyclin receptor agonists and endothelin receptor antagonists. These developments have led to substantial improvements in mortality rate in recent decades. Recently, long-term studies have demonstrated sustained progression-free survival and have created a new paradigm of initial combination therapy. Despite these targeted therapies, PAH is still associated with significant morbidity and mortality. As such, further research into broadening our understanding of PAH pathophysiology is underway with potential of increasing the repertoire of drugs available.